Pirtobrutinib,Venetoclax,Rituximab,ibrutinib,acalabrutinib
roche,eli lilly,abbvie,astrazeneca,janssen
['bruin study', 'cll', ' ibru', ' ofa ', 'fil,veral,12', 'pirto', 'acalabrutinib', 'leukemia', 'bruin', '2018', 'lymsm', 'valent ,(-prevalent),(-equivalent),(-bivalent)', 'valent ,(-prevalent)']
congress | #ash22 , discussed results from a cohort of pts with richter transformation in the bruin study. treatment with pirtobrutinib was well tolerated with a med os of 13.1mo. there was a low rate of grade 3 or higher teae.
#lymsm #medicalcongress 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm